SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
duxiao
Lv7
4910 积分
2023-02-07 加入
最近求助
最近应助
互助留言
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype
7小时前
已完结
Discussion on the Relationship and Influence Factors of the Limit of Detection and the Sensitivity of Analytical Methods
8小时前
已完结
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
2个月前
已完结
Advances in the treatment of systemic lupus erythematosus
2个月前
已完结
Elranatamab: a new promising BispAb in multiple myeloma treatment
2个月前
已完结
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
2个月前
已完结
A role for STEAP2 in prostate cancer progression
3个月前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
3个月前
已完结
A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update
3个月前
已完结
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
3个月前
已完结
没有进行任何应助
感谢
7小时前
感谢
8小时前
感谢
2个月前
感谢
2个月前
感谢
2个月前
感谢
2个月前
感谢
3个月前
感谢
3个月前
感谢
3个月前
感谢
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论